An observational study in Treatment-resistant Schizophrenia, sponsored by Shanghai Mental Health Center. Not yet recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Shanghai Mental Health Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Approximately 20-30% of patients with schizophrenia show poor response to standard antipsychotic medications, which is defined as treatment- resistant schizophrenia (TRS), yet the underlying pathological mechanisms remain largely unknown. Brain organoids, also referred to as cerebral organoids, have emerged as a promising tool for modeling neurodevelopmental disorders in the laboratory. In this observational study, blood samples will be collected from TRS patients and their family members to generate personalized brain organoids. This study aims to elucidate the mechanisms of TRS and to provide preclinical evidence for developing personalized intervention strategies.
This study investigates early-onset treatment-resistant schizophrenia using personalized brain organoids. Blood samples will be collected from patients with schizophrenia and their family members to obtain peripheral blood mononuclear cells (PBMCs). Induced pluripotent stem cells (iPSCs) will be reprogrammed from these PBMCs and differentiated into brain organoids that mimic individual brain development. Multi-omics analyses will be performed on these models to explore the biological heterogeneity underlying TRS. Various drugs will be tested on the organoids to identify which medications are effective for each patient. Clinical data including symptoms and cognition will be collected and integrated with laboratory findings. This study aims to provide preclinical evidence for developing personalized targeted interventions for TRS and to establish a foundation for future precision medicine clinical trials in this population.
53 studies on the registry are indexed under Schizophrenia, Treatment-Resistant; 22 are open to participants now.
Browse Schizophrenia, Treatment-Resistant studies →Shanghai Mental Health Center is the lead sponsor of 277 studies on the registry; 96 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with early-onset treatment-resistant schizophrenia and their first-degree relatives will be recruited from inpatient units at Shanghai Mental Health Center.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meet the diagnostic criteria for treatment-resistant schizophrenia, defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Association Between Organoid-derived Biological Characteristics and Clinical Phenotypes
The associations between biological characteristics of patient-derived brain organoids and clinical phenotypes of patients with early-onset treatment-resistant schizophrenia (EO-TRS) will be investigated. Psychiatric symptom severity will be assessed using the Positive and Negative Syndrome Scale (PANSS), and cognitive function will be evaluated using the MATRICS Consensus Cognitive Battery (MCCB). The biological characteristics of brain organoids will be evaluated through transcriptomic and morphological analyses. Transcriptomic analyses will be performed to identify differentially expressed genes across organoids from different patients, while morphological analyses will assess neuronal structure and synaptic formation. Correlation analyses will be conducted to explore the relationships between organoid-derived biological features and clinical symptom severity and cognitive performance.
Time frame: At baseline clinical assessment and corresponding brain organoid characterization
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Oct 2028, 21 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Schizophrenia, Treatment-Resistant →
Shanghai Mental Health Center →